The diagnostic value of DNA hypermethylation in stool for colorectal cancer: A meta-analysis

Qian, Liyu; Zhang, Wei

doi:10.4103/0973-1482.151534

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several meta-analyses assessing the diagnostic value of stool DNA testing [ 343 , 344 , 345 , 346 , 347 , 348 ]. Zhai et al reported the pooled sensitivities for single- and multiple-gene stool DNA (methylation and mutation) tests in CRC to be 48.0% and 77.8%, respectively, and the pooled specificity for single- and multiple-gene assays to be 97.0% and 92.7%, respectively [ 344 ].…”

Section: Diagnostic Stool Biomarkers For Colorectal Cancermentioning

confidence: 99%

“…Zhang et al reported a sensitivity ranging from 51% for adenomas to 73% for CRCs and a specificity of 92% [ 345 ]. In another meta-analysis, the pooled sensitivity of the combined single- and multiple-gene DNA hypermethylation tests on stool specimens was 0.71 and specificity was 0.92 for [ 343 ]. In Mojtabanezhads et al‘s meta-analysis, this method was shown to have a lower efficiency than reported in previous meta-analyses: the sensitivity for CRC and adenomas was 56.5% and 32.6%, respectively, and the specificity was 93.2% for CRC and adenomas [ 347 ].…”

Section: Diagnostic Stool Biomarkers For Colorectal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Novel Diagnostic Biomarkers in Colorectal Cancer

Zygulska¹,

Pierzchalski

2022

IJMS

118

View full text Add to dashboard Cite

Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease associated with a number of genetic or somatic mutations. Diagnostic markers are used for risk stratification and early detection, which might prolong overall survival. Nowadays, the widespread use of semi-invasive endoscopic methods and feacal blood tests characterised by suboptimal accuracy of diagnostic results has led to the detection of cases at later stages. New molecular noninvasive tests based on the detection of CRC alterations seem to be more sensitive and specific then the current methods. Therefore, research aiming at identifying molecular markers, such as DNA, RNA and proteins, would improve survival rates and contribute to the development of personalized medicine. The identification of “ideal” diagnostic biomarkers, having high sensitivity and specificity, being safe, cheap and easy to measure, remains a challenge. The purpose of this review is to discuss recent advances in novel diagnostic biomarkers for tumor tissue, blood and stool samples in CRC patients.

show abstract

Section: Diagnostic Stool Biomarkers For Colorectal Cancermentioning

confidence: 99%

Section: Diagnostic Stool Biomarkers For Colorectal Cancermentioning

confidence: 99%

Novel Diagnostic Biomarkers in Colorectal Cancer

Zygulska¹,

Pierzchalski

2022

IJMS

118

View full text Add to dashboard Cite

show abstract

“…In another study for methylated single- and multiple-gene tests in fecal samples, Luo et al demonstrated an overall sensitivity of 62% and 54%, and a specificity of 89% and 88% in CRC and adenoma patients, respectively [ 60 ]. In the Qian et al, meta-analysis, the pooled sensitivity of the combined single- and multiple-gene DNA hypermethylation in stool was 71% and its specificity was 92% for CRC [ 61 ]. In the current study, single-gene stool DNA methylation analysis had a sensitivity (specificity) for CRC and adenoma of 56.5% (93.2%) and 32.6% (93.2%), respectively.…”

Section: Discussionmentioning

confidence: 99%

The importance of stool DNA methylation in colorectal cancer diagnosis: A meta-analysis

et al. 2018

View full text Add to dashboard Cite

A large number of tumor-related methylated genes have been suggested to be of diagnostic and prognostic values for CRC when analyzed in patients' stool samples; however, reported sensitivities and specificities have been inconsistent and widely varied. This meta-analysis was conducted to assess the detection accuracy of stool DNA methylation assay in CRC, early stages of CRC (advanced adenoma, non-advanced adenomas) and hyperplastic polyps, separately. We searched MEDLINE, Web of Science, Scopus and Google Scholar databases until May 1, 2016. From 469 publications obtained in the initial literature search, 38 studies were included in the final analysis involving 4867 individuals. The true positive, false positive, true negative and false negative of a stool-based DNA methylation biomarker using all single-gene tests considering a certain gene; regardless of a specific gene were pooled and studied in different categories. The sensitivity of different genes in detecting different stages of CRC ranged from 0% to 100% and the specificities ranged from 73% to 100%. Our results elucidated that SFRP1 and SFRP2 methylation possessed promising accuracy for detection of not only CRC (DOR: 31.67; 95%CI, 12.31–81.49 and DOR: 35.36; 95%CI, 18.71–66.84, respectively) but also the early stages of cancer, adenoma (DOR: 19.72; 95%CI, 6.68–58.25 and DOR: 13.20; 95%CI, 6.01–28.00, respectively). Besides, NDRG4 could be also considered as a significant diagnostic marker gene in CRC (DOR: 24.37; 95%CI, 10.11–58.73) and VIM in adenoma (DOR: 15.21; 95%CI, 2.72–85.10). In conclusion, stool DNA hypermethylation assay based on the candidate genes SFRP1, SFRP2, NDRG4 and VIM could offer potential diagnostic value for CRC based on the findings of this meta-analysis.

show abstract

“…Other stool based tumour biomarkers included SDC2, with reported sensitivity of 0.81 (95% CI 0.74 to 0.86), specificity of 0.95 (95% CI 0.93 to 0.96) and AUC of 0.96 (95% CI 0.94 to 0.97)75; methylation of multiple DNAs has a sensitivity of 0.71 (95% CI 0.69 to 0.73), specificity of 0.92 (95% CI 0.90 to 0.93) and AUC of 0.93 (95% CI 0.91 to 0.95), and for multiple markers, sensitivity is 0.76 (95% CI 0.71 to 0.80), specificity 0.88 (95% CI 0.84 to 0.91) and AUC of 0.91 in two respective studies 76 77…”

Section: Executive Summary Of Key Recommendationsmentioning

confidence: 99%

Joint Asian Pacific Association of Gastroenterology (APAGE)–Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia

Chan

Wong

Chan

et al. 2023

Gut

View full text Add to dashboard Cite

Screening for colorectal cancer (CRC) is effective in reducing CRC related mortality. Current screening methods include endoscopy based and biomarker based approaches. This guideline is a joint official statement of the Asian Pacific Association of Gastroenterology (APAGE) and the Asian Pacific Society of Digestive Endoscopy (APSDE), developed in response to the increasing use of, and accumulating supportive evidence for the role of, non-invasive biomarkers for the diagnosis of CRC and its precursor lesions. A systematic review of 678 publications and a two stage Delphi consensus process involving 16 clinicians in various disciplines was undertaken to develop 32 evidence based and expert opinion based recommendations for the use of faecal immunochemical tests, faecal based tumour biomarkers or microbial biomarkers, and blood based tumour biomarkers for the detection of CRC and adenoma. Comprehensive up-to-date guidance is provided on indications, patient selection and strengths and limitations of each screening tool. Future research to inform clinical applications are discussed alongside objective measurement of research priorities. This joint APAGE–APSDE practice guideline is intended to provide an up-to-date guide to assist clinicians worldwide in utilising non-invasive biomarkers for CRC screening; it has particular salience for clinicians in the Asia-Pacific region.

show abstract

The diagnostic value of DNA hypermethylation in stool for colorectal cancer: A meta-analysis

Abstract: These results indicate a great diagnostic potential for DNA hypermethylation as a reliable marker in stool for CRC.

Cited by 6 publications

References 24 publications

Novel Diagnostic Biomarkers in Colorectal Cancer

Novel Diagnostic Biomarkers in Colorectal Cancer

The importance of stool DNA methylation in colorectal cancer diagnosis: A meta-analysis

Joint Asian Pacific Association of Gastroenterology (APAGE)–Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia

Contact Info

Product

Resources

About